Cargando…
DDRE-04. THE COMBINED TREATMENT OF L-ASPARAGINASE AND 6-DIAZO-5-OXO-L-NORLEUCINE INHIBIT THE PROLIFERATION OF TEMOZOLOMIDE-SENSITIVE OR RESISTANT GLIOBLASTOMA CELLS
Glioblastoma is one of the aggressive brain tumors with a 5-year survival rate of < 10%. The standard treatment is maximal safe resection, followed by radiation therapy and temozolomide (TMZ). Clinically, the resistance to TMZ is a big problem. Cancer cells have been revealed to show different me...
Autores principales: | Ohba, Shigeo, Hirose, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992212/ http://dx.doi.org/10.1093/noajnl/vdab024.026 |
Ejemplares similares
-
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
por: Cervantes-Madrid, Diana, et al.
Publicado: (2015) -
Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
por: Huber, K. R., et al.
Publicado: (1987) -
Discovery of tert-Butyl Ester Based
6-Diazo-5-oxo-l-norleucine Prodrugs
for Enhanced Metabolic Stability and Tumor Delivery
por: Novotná, Kateřina, et al.
Publicado: (2023) -
DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA
por: Eyme, Katharina M, et al.
Publicado: (2021) -
DDRE-15. THE EVOLUTIONARY ENIGMA OF FATTY ACID DESATURATION IN GLIOBLASTOMA
por: Oatman, Nicole, et al.
Publicado: (2021)